[HTML][HTML] Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations
…, E Snyder, W Bensinger, E Copelan, C Hosing… - Biology of Blood and …, 2014 - Elsevier
Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment
for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the …
for malignancies such as multiple myeloma (MM) and lymphomas. Various changes in the …
Concise review: umbilical cord blood transplantation: past, present, and future
J Munoz, N Shah, K Rezvani, C Hosing… - Stem cells …, 2014 - academic.oup.com
… Chitra Hosing , Chitra Hosing … Dahi PB, Ponce DM, Byam C et al. Prospective evaluation
of alternative donor availability in 708 patients: Improved allograft access with enlarging CB …
of alternative donor availability in 708 patients: Improved allograft access with enlarging CB …
[HTML][HTML] Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors
…, K Cao, M Daher, C Hosing… - … England Journal of …, 2020 - Mass Medical Soc
Background Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable
clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic …
clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic …
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
…, RT Kamble, G Carrum, CM Hosing… - Blood, The Journal …, 2013 - ashpublications.org
Autologous T cells expressing a CD19-specific chimeric antigen receptor (CD19.CAR) are
active against B-cell malignancies, but it is unknown whether allogeneic CD19.CAR T cells …
active against B-cell malignancies, but it is unknown whether allogeneic CD19.CAR T cells …
[HTML][HTML] Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma
…, NL Bartlett, T Siddiqi, JC Chavez, CM Hosing… - Molecular Therapy, 2017 - cell.com
Outcomes for patients with refractory diffuse large B cell lymphoma (DLBCL) are poor. In the
multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-…
multicenter ZUMA-1 phase 1 study, we evaluated KTE-C19, an autologous CD3ζ/CD28-…
Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma
…, JL Kaufman, RT Maziarz, C Hosing… - Blood, The Journal …, 2009 - ashpublications.org
This phase 3, multicenter, randomized (1:1), double-blind, placebo-controlled study evaluated
the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in …
the safety and efficacy of plerixafor with granulocyte colony-stimulating factor (G-CSF) in …
[HTML][HTML] Myeloablative autologous stem-cell transplantation for severe scleroderma
…, GE Georges, S Heimfeld, C Hosing… - … England Journal of …, 2018 - Mass Medical Soc
Background Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma)
often has a devastating outcome. We compared myeloablative CD34+ selected autologous …
often has a devastating outcome. We compared myeloablative CD34+ selected autologous …
[HTML][HTML] Cord-blood engraftment with ex vivo mesenchymal-cell coculture
…, C Hosing, R Champlin, C Bollard… - … England Journal of …, 2012 - Mass Medical Soc
Background Poor engraftment due to low cell doses restricts the usefulness of umbilical-cord-blood
transplantation. We hypothesized that engraftment would be improved by …
transplantation. We hypothesized that engraftment would be improved by …
[HTML][HTML] Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B …
…, JW Fay, DA Rizzieri, CM Hosing… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
… (C) Changes in expression of selected surface markers on monocytes and T cells. … was
received; those relationships marked with a “C” were compensated. For a detailed description of …
received; those relationships marked with a “C” were compensated. For a detailed description of …
[HTML][HTML] Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
…, K Rezvani, D Marin, U Popat, C Hosing… - The Journal of …, 2016 - Am Soc Clin Investig
BACKGROUND. T cells expressing antigen-specific chimeric antigen receptors (CARs) improve
outcomes for CD19-expressing B cell malignancies. We evaluated a human application …
outcomes for CD19-expressing B cell malignancies. We evaluated a human application …